Optimal Pharmacologic Treatment of ADPKD: What You Need to Know – Monitoring and Risk Mitigation

Posted In CYSTIC RENAL DISEASES, Polycystic kidney disease, NEPHROLOGY, cystic renal disease

Neera Dahl, MD, PhD

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Serve(d) as a director, officer, partner, em

Optimal Pharmacologic Treatment of ADPKD: What You Need to Know – Monitoring and Risk Mitigation

Submit a Comment Cancel reply

You must be logged in to post a comment.

WELCOME TO RENAL MEDCASE – A KIDNEYTUBE CHANNEL MEMBER

Optimal Pharmacologic Treatment of ADPKD: What You Need to Know – Monitoring and Risk Mitigation

Free CME

Submit a Comment Cancel reply